SFPM(SZ:002737) Sou Hu Cai Jing·2025-08-12 09:53Group 1 - The core viewpoint of the news is that Aihua Pharmaceutical (葵花药业) has experienced significant declines in revenue and net profit in its latest quarterly report, indicating potential challenges for the company moving forward [1][3] - As of August 12, 2025, Aihua Pharmaceutical's stock closed at 16.13 yuan, down 0.37%, with a trading volume of 57,200 hands and a transaction amount of 92.5496 million yuan [1] - The company's main funds saw a net outflow of 13.5238 million yuan, accounting for 14.61% of the transaction amount, with large orders contributing significantly to this outflow [1] Group 2 - For the first quarter of 2025, Aihua Pharmaceutical reported total operating revenue of 663 million yuan, a year-on-year decrease of 56.30%, and a net profit attributable to shareholders of 57.1118 million yuan, down 77.62% year-on-year [1] - The company's liquidity ratios are strong, with a current ratio of 4.148 and a quick ratio of 3.308, while the debt-to-asset ratio stands at 19.49% [1] - Aihua Pharmaceutical has made investments in 32 companies and has participated in six bidding projects, indicating active engagement in business expansion [2]